Please login to the form below

Not currently logged in
Email:
Password:

Cardio3 BioSciences appoints Warren Sherman chief medical officer

He joins the biopharma firm from Columbia University Medical Center

edit-C3BS_Dr-Warren-ShermanBelgian biopharma firm Cardio3 BioSciences has named Warren Sherman as its chief medical officer.

Sherman has over 30 years' cardiology experience, with a focus on cell-based therapies for treating patients post-myocardial infarction and with heart failure.

He will assume the role at the cardiovascular disease-focused company from November 1.

He joins from Columbia University Medical Center, where he served in numerous roles including director of stem cell research and regenerative medicine and interventional cardiologist.

Sherman said: “I am thrilled to be joining Cardio3 BioSciences as chief medical officer at such an exciting time in its clinical development phase.

“The accomplishments of this young and dynamic company are remarkable, and it is an enormous opportunity for me to be part of the most promising project in the fields of cell therapy and other treatments for cardiovascular diseases.”

Sherman is also founder of the Cardiovascular Research Foundation's international conference on cell therapy for cardiovascular disease (IC3D), a meeting for healthcare experts dedicated to the evolving file of cell-based therapies for the repair and regeneration of cardiac and vascular disease.

Christian Homsy, CEO of Cardio3 BioSciences, added: “We are very pleased to be able to count on Warren Sherman's expertise in clinical application, as well as his renowned scientific outreach for the further development of Cardio3 BioSciences' future projects in regenerative therapies and cardiovascular diseases.”

3rd November 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics